Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4

被引：0
作者：
Sridhar, Vikas S. [1 ,2 ,3 ]
Davies, Michael J. [4 ]
Banks, Phillip [4 ]
Girard, Manon [4 ]
Carroll, Amy K. [4 ]
Cherney, David Z. I. [1 ,2 ,3 ]
机构：
[1] Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON, Canada
[2] Univ Hlth Network, Dept Med, Div Nephrol, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Toronto, ON, Canada
[4] Lexicon Pharmaceut Inc, The Woodlands, TX USA
来源：
DIABETES OBESITY & METABOLISM | 2024年
关键词：
anaemia; chronic kidney disease; SGLT2; inhibitors; type; 2; diabetes;
D O I：
10.1111/dom.16079
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 8 条
[1]   Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease [J].
Bhatt, Deepak L. ;
Szarek, Michael ;
Pitt, Bertram ;
Cannon, Christopher P. ;
Leiter, Lawrence A. ;
McGuire, Darren K. ;
Lewis, Julia B. ;
Riddle, Matthew C. ;
Inzucchi, Silvio E. ;
Kosiborod, Mikhail N. ;
Cherney, David Z. I. ;
Dwyer, Jamie P. ;
Scirica, Benjamin M. ;
Bailey, Clifford J. ;
Diaz, Rafael ;
Ray, Kausik K. ;
Udell, Jacob A. ;
Lopes, Renato D. ;
Lapuerta, Pablo ;
Steg, P. Gabriel .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02) :129-139
[2]   Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease [J].
Cherney, David Z. I. ;
Ferrannini, Ele ;
Umpierrez, Guillermo E. ;
Peters, Anne L. ;
Rosenstock, Julio ;
Powell, David R. ;
Davies, Michael J. ;
Banks, Phillip ;
Agarwal, Rajiv .
DIABETES OBESITY & METABOLISM, 2023, 25 (06) :1646-1657
[3]   Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment [J].
Cherney, David Z. I. ;
Ferrannini, Ele ;
Umpierrez, Guillermo E. ;
Peters, Anne L. ;
Rosenstock, Julio ;
Carroll, Amy K. ;
Lapuerta, Pablo ;
Banks, Phillip ;
Agarwal, Rajiv .
DIABETES OBESITY & METABOLISM, 2021, 23 (12) :2632-2642
[4]   Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease [J].
Mazer, C. David ;
Hare, Gregory M. T. ;
Connelly, Philip W. ;
Gilbert, Richard E. ;
Shehata, Nadine ;
Quan, Adrian ;
Teoh, Hwee ;
Leiter, Lawrence A. ;
Zinman, Bernard ;
Juni, Peter ;
Zuo, Fei ;
Mistry, Nikhil ;
Thorpe, Kevin E. ;
Goldenberg, Ronald M. ;
Yan, Andrew T. ;
Connelly, Kim A. ;
Verma, Subodh .
CIRCULATION, 2020, 141 (08) :704-707
[5]   Proximal versus distal diuretics in congestive heart failure [J].
Nardone, Massimo ;
Sridhar, Vikas S. ;
Yau, Kevin ;
Odutayo, Ayodele ;
Cherney, David Z., I .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (09) :1392-1403
[6]   Alleviation of Anemia by SGLT2 Inhibitors in Patients with CKD: Mechanisms and Results of Long-Term Placebo-Controlled Trials [J].
Packer, Milton .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 19 (04) :531-534
[7]   Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis [J].
Tian, Qi ;
Guo, Keyu ;
Deng, Jiayi ;
Zhong, Yanjun ;
Yang, Lin .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (02) :540-547
[8]   How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial [J].
Wanner, Christoph ;
Nangaku, Masaomi ;
Kraus, Bettina J. ;
Zinman, Bernard ;
Mattheus, Michaela ;
Hantel, Stefan ;
Schumacher, Martin ;
Ohneberg, Kristin ;
Schmoor, Claudia ;
Inzucchi, Silvio E. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (09) :1504-1513
1